Disulfiram/copper complex inhibiting NFκB activity and potentiating cytotoxic effect of gemcitabine on colon and breast cancer cell lines

被引：113

作者：

Guo, Xiaoxia ^{[1
]}

Xu, Bing ^{[1
,2
]}

Pandey, Shuchita ^{[1
]}

Goessl, Elisabeth ^{[1
]}

Brown, James ^{[1
]}

Armesilla, Angel L. ^{[1
]}

Darling, John L. ^{[1
]}

Wang, Weiguang ^{[1
]}

机构：

[1] Wolverhampton Univ, Sch Appl Sci, Res Inst Healthcare Sci, Wolverhampton WV1 1SB, England

[2] So Med Univ, Nanfang Hosp, Guangzhou, Guangdong, Peoples R China

来源：

CANCER LETTERS | 2010年 / 290卷 / 01期

关键词：

NF kappa B; Gemcitabine resistance; Disulfiram; Colorectal cancer; Breast cancer; PANCREATIC-CANCER; LUNG-CANCER; 2'; 2'-DIFLUORODEOXYCYTIDINE GEMCITABINE; DEOXYCYTIDINE KINASE; ANTITUMOR-ACTIVITY; STIMULATING FACTOR; PLUS CAPECITABINE; OXIDATIVE STRESS; TUMOR-CELLS; RESISTANCE;

D O I：

10.1016/j.canlet.2009.09.002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Most of the gemcitabine (dFdC) resistant cell lines manifested high NF kappa B activity. The NF kappa B activity can be induced by dFdC and 5-FU exposure. The chemosensitizing effect of disulfiram (DS), an anti-alcoholism drug and NF kappa B inhibitor, and copper (Cu) on the chemoresistant cell lines was examined. The DS/Cu complex significantly enhanced the cytotoxicity of dFdC (resistant cells: 12.2-1085-fold) and completely reversed the dFdC resistance in the resitant cell lines. The dFdC-induced NF kappa B activity was markedly inhibited by DS/Cu complex. The data from this study indicated that DS may be used in clinic to improve the therapeutic effect of dFdC in breast and colon cancer patients. (C) 2009 Published by Elsevier Ireland Ltd.

引用

页码：104 / 113

页数：10

共 57 条

[41]

Ruiz van Haperen V W, 1993, Biochem Pharmacol, V46, P762, DOI 10.1016/0006-2952(93)90566-F

[42] Role of NF-κB in p53-mediated programmed cell death [J].

Ryan, KM ;

Ernst, MK ;

Rice, NR ;

Vousden, KH .

NATURE, 2000, 404 (6780) :892-897

[43] NF-κB inhibits TNF-induced accumulation of ROS that mediate prolonged MAPK activation and necrotic cell death [J].

Sakon, S ;

Xue, X ;

Takekawa, M ;

Sasazuki, T ;

Okazaki, T ;

Kojima, Y ;

Piao, JH ;

Yagita, H ;

Okumura, K ;

Doi, T ;

Nakano, H .

EMBO JOURNAL, 2003, 22 (15) :3898-3909

[44] Current adjuvant and targeted therapies for pancreatic adenocarcinoma [J].

Sanchez, Sabrina E. ;

Trevino, Jose G. .

CURRENT MEDICINAL CHEMISTRY, 2008, 15 (17) :1674-1683

[45] Establishment of gemcitabine-resistant human pancreatic cancer cells and effect of Brefeldin-A on the resistant cell line [J].

Togawa, A ;

Ito, H ;

Kimura, F ;

Shimizu, H ;

Ohtsuka, M ;

Shimamura, F ;

Yoshidome, H ;

Katoh, A ;

Miyazaki, M .

PANCREAS, 2003, 27 (03) :220-224

[46] Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines [J].

Tolis, C ;

Peters, GJ ;

Ferreira, CG ;

Pinedo, HM ;

Giaccone, G .

EUROPEAN JOURNAL OF CANCER, 1999, 35 (05) :796-807

[47] Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy? [J].

Ueno, H. ;

Kiyosawa, K. ;

Kaniwa, N. .

BRITISH JOURNAL OF CANCER, 2007, 97 (02) :145-151

[48] Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study [J].

Villalona-Calero, M. A. ;

Otterson, G. A. ;

Wientjes, M. G. ;

Weber, F. ;

Bekaii-Saab, T. ;

Young, D. ;

Murgo, A. J. ;

Jensen, R. ;

Yeh, T. -K. ;

Wei, Y. ;

Zhang, Y. ;

Eng, C. ;

Grever, M. ;

Au, J. L. -S. .

ANNALS OF ONCOLOGY, 2008, 19 (11) :1903-1909

[49] TNF- and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-kappa B [J].

Wang, CY ;

Mayo, MW ;

Baldwin, AS .

SCIENCE, 1996, 274 (5288) :784-787

[50] Constitutive nuclear factor-kappa B mRNA, protein overexpression and enhanced DNA-binding activity in thymidylate synthase inhibitor-resistant tumour cells [J].

Wang, W ;

Cassidy, J .

BRITISH JOURNAL OF CANCER, 2003, 88 (04) :624-629

← 1 2 3 4 5 6 →